Cargando…

Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p)

We analyzed the treatment of newly diagnosed and relapsed/refractory multiple myeloma (NDMM/RRMM) patients with del(17p). Thirteen prospective studies that evaluated 3,187 MM patients, including 685with del(17p), were included in our meta-analysis. The incidence of del(17p) in NDMM and RRMM patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jinghua, Yang, Hui, Liang, Xiaochan, Wang, Yuxin, Hou, Jian, Liu, Yanqin, Wang, Jigang, Zhou, Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617517/
https://www.ncbi.nlm.nih.gov/pubmed/28977957
http://dx.doi.org/10.18632/oncotarget.18722
_version_ 1783267005949804544
author Liu, Jinghua
Yang, Hui
Liang, Xiaochan
Wang, Yuxin
Hou, Jian
Liu, Yanqin
Wang, Jigang
Zhou, Fan
author_facet Liu, Jinghua
Yang, Hui
Liang, Xiaochan
Wang, Yuxin
Hou, Jian
Liu, Yanqin
Wang, Jigang
Zhou, Fan
author_sort Liu, Jinghua
collection PubMed
description We analyzed the treatment of newly diagnosed and relapsed/refractory multiple myeloma (NDMM/RRMM) patients with del(17p). Thirteen prospective studies that evaluated 3,187 MM patients, including 685with del(17p), were included in our meta-analysis. The incidence of del(17p) in NDMM and RRMM patients was similar (13% vs. 14%, respectively, P = 0.64, I(2) = 94%). The overall response rate (ORR) to new agents was 40.5% and 67.1%, respectively, in RRMM patients with or without del(17p) (P = 0.1, I(2) = 63.9%). NDMM patients with del(17p) treated with PAD (bortezomib, adriamycin, and dexamethasone) induction therapy followed by bortezomib maintenance therapy had higher progression-free survival (PFS) (25.7 vs. 12-14.6 months) and overall survival (OS) (62% vs. 8% at 36 months) than those treated with PD (bortezomib and dexamethasone) or VAD (vincristine, adriamycin, and dexamethasone). PFS among RRMM patients with del(17p) treated with D (single-agent dexamethasone), Rd/VRd (lenalidomide and dexamethasone/bortezomib and Rd), KRd (carfilzomib and Rd), IRd (ixazomib and Rd), ERd (elotuzumab and Rd), or P+D (pomalidomide and dexamethasone) was 1.1, 2-14.9, 24.5, 15.7, 21.2, and 4.6-7.3 months, respectively. The OS of patients treated with D or K (single-agent carfilzomib), Rd/VRd, ERd, or P+D was 7.7, 7, 4.7–36.4, > 42.3, and 12–12.6 months, respectively. PFS among RRMM patients without del(17p) treated with D, Rd/VRd, ERd, or P+D was 2.3, 8.2-14.8, 18.5, and 4.2 months, while OS was 9, 23-40.8, 42.3, and 14 months, respectively. Thus bortezomib maintenance therapy improves the prognosis of NDMM patients with del(17p). Combined treatment with carfilzomib or elotuzumab and Rd, or pomalidomide with low-dose dexamethasone, improves the outcomes of RRMM patients with del(17p).
format Online
Article
Text
id pubmed-5617517
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56175172017-10-03 Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p) Liu, Jinghua Yang, Hui Liang, Xiaochan Wang, Yuxin Hou, Jian Liu, Yanqin Wang, Jigang Zhou, Fan Oncotarget Meta-Analysis We analyzed the treatment of newly diagnosed and relapsed/refractory multiple myeloma (NDMM/RRMM) patients with del(17p). Thirteen prospective studies that evaluated 3,187 MM patients, including 685with del(17p), were included in our meta-analysis. The incidence of del(17p) in NDMM and RRMM patients was similar (13% vs. 14%, respectively, P = 0.64, I(2) = 94%). The overall response rate (ORR) to new agents was 40.5% and 67.1%, respectively, in RRMM patients with or without del(17p) (P = 0.1, I(2) = 63.9%). NDMM patients with del(17p) treated with PAD (bortezomib, adriamycin, and dexamethasone) induction therapy followed by bortezomib maintenance therapy had higher progression-free survival (PFS) (25.7 vs. 12-14.6 months) and overall survival (OS) (62% vs. 8% at 36 months) than those treated with PD (bortezomib and dexamethasone) or VAD (vincristine, adriamycin, and dexamethasone). PFS among RRMM patients with del(17p) treated with D (single-agent dexamethasone), Rd/VRd (lenalidomide and dexamethasone/bortezomib and Rd), KRd (carfilzomib and Rd), IRd (ixazomib and Rd), ERd (elotuzumab and Rd), or P+D (pomalidomide and dexamethasone) was 1.1, 2-14.9, 24.5, 15.7, 21.2, and 4.6-7.3 months, respectively. The OS of patients treated with D or K (single-agent carfilzomib), Rd/VRd, ERd, or P+D was 7.7, 7, 4.7–36.4, > 42.3, and 12–12.6 months, respectively. PFS among RRMM patients without del(17p) treated with D, Rd/VRd, ERd, or P+D was 2.3, 8.2-14.8, 18.5, and 4.2 months, while OS was 9, 23-40.8, 42.3, and 14 months, respectively. Thus bortezomib maintenance therapy improves the prognosis of NDMM patients with del(17p). Combined treatment with carfilzomib or elotuzumab and Rd, or pomalidomide with low-dose dexamethasone, improves the outcomes of RRMM patients with del(17p). Impact Journals LLC 2017-06-27 /pmc/articles/PMC5617517/ /pubmed/28977957 http://dx.doi.org/10.18632/oncotarget.18722 Text en Copyright: © 2017 Liu et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Meta-Analysis
Liu, Jinghua
Yang, Hui
Liang, Xiaochan
Wang, Yuxin
Hou, Jian
Liu, Yanqin
Wang, Jigang
Zhou, Fan
Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p)
title Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p)
title_full Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p)
title_fullStr Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p)
title_full_unstemmed Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p)
title_short Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p)
title_sort meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p)
topic Meta-Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617517/
https://www.ncbi.nlm.nih.gov/pubmed/28977957
http://dx.doi.org/10.18632/oncotarget.18722
work_keys_str_mv AT liujinghua metaanalysisoftheefficacyoftreatmentsfornewlydiagnosedandrelapsedrefractorymultiplemyelomawithdel17p
AT yanghui metaanalysisoftheefficacyoftreatmentsfornewlydiagnosedandrelapsedrefractorymultiplemyelomawithdel17p
AT liangxiaochan metaanalysisoftheefficacyoftreatmentsfornewlydiagnosedandrelapsedrefractorymultiplemyelomawithdel17p
AT wangyuxin metaanalysisoftheefficacyoftreatmentsfornewlydiagnosedandrelapsedrefractorymultiplemyelomawithdel17p
AT houjian metaanalysisoftheefficacyoftreatmentsfornewlydiagnosedandrelapsedrefractorymultiplemyelomawithdel17p
AT liuyanqin metaanalysisoftheefficacyoftreatmentsfornewlydiagnosedandrelapsedrefractorymultiplemyelomawithdel17p
AT wangjigang metaanalysisoftheefficacyoftreatmentsfornewlydiagnosedandrelapsedrefractorymultiplemyelomawithdel17p
AT zhoufan metaanalysisoftheefficacyoftreatmentsfornewlydiagnosedandrelapsedrefractorymultiplemyelomawithdel17p